|
|
|
23.10.25 - 18:15
|
Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders (Business Wire)
|
|
|
GENEVA & LAKE FOREST, Calif.--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today announced that STAAR and Alcon have agreed to adjourn STAAR's Special Meeting of Stockholders (the “Special Meeting”) scheduled for October 23, 2025, in connection with STAAR's merger agreement with Alcon. No other business will be conducted at the Special Meeting.
STAAR is adjourning the Special Meeting until 8:30 a.m. Pacific Time on November 6, 2025. The record date for STAAR stockholders eligible to vote at the Special Meeting remains the close of business on September 12, 2025.
Stockholders with questions about voting their shares should contact STAAR's proxy solicitor, Innisfree M&A Incorporated, toll-free at +1 877-750-8233. Banks and brokerage firms, please call +1 212-750-5833.
About Alcon
Alcon helps people see brilliantly. As the global le...
|
|
|
|
|
|
|
20.10.25 - 23:33
|
Yunqi Capital Issues Letter to STAAR Surgicals Board Calling for Timely Convening of the Special Meeting to Vote on the Alcon Transaction (Business Wire)
|
|
|
Shareholders Have the Information They Need to Make an Informed Vote
Preliminary Net Sales Results for Third Quarter Underscore a Positive Trajectory
Continues to Oppose the Proposed Merger and Will Vote AGAINST at the Special MeetingHONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ:STAA), today issued the following letter to the Board of Directors of STAAR regarding Yunqi's opposition to the proposed sale to Alcon Inc. (SIX/NYSE:ALC) on the terms announced on August 5, 2025.
The text of the letter to the Board is as follows:
October 21, 2025
STAAR Surgical Company
25510 Commercentre Drive
Lake Forest, CA 92630
Dear Members of the Board:
We are writing to express concern over recent representations by the Company regarding the proposed merger with Alcon, to urge you to hold the special meeting of shareholders ...
|
|
|
|
|
17.10.25 - 14:06
|
Broadwood Partners Issues Letter to STAAR Surgical′s Board Urging it to Allow Timely Shareholder Vote on Alcon Sale (Business Wire)
|
|
|
Calls on Board to Avoid Temptation to Delay Meeting or Further Mislead Shareholders
Broadwood Continues to Urge Shareholders to Vote “AGAINST” Proposed TransactionNEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA). Broadwood, which owns 27.5% of STAAR's outstanding common shares, urges its fellow shareholders to vote on its GREEN Proxy Card “AGAINST” the proposed acquisition of STAAR by Alcon Inc. (“Alcon”) (NYSE: ALC) on the terms announced on August 5, 2025.
Shareholders can find additional information at www.LetSTAARShine.com.
The text of the letter to the Board is as follows:
October 17, 2025
STAAR Surgical Company
25510 Commercentre Dr.
Lake Forest, CA 92630
Dear Members of the Board:
With incomplete information and after a poorly designed process, you decided to sell STAAR to Alcon fo...
|
|
|
|
|
16.10.25 - 22:18
|
STAAR Surgical Affirms that No Acquisition Proposals Have Been Received From Any Party Other Than Alcon (Business Wire)
|
|
|
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued the following statement:
Broadwood Partners' statements and assertions regarding interest in STAAR are misleading and distort the truth. Broadwood is misrepresenting introductory emails as offers to acquire STAAR. As previously disclosed, the communications from Party A and B were not offers and contained no information relating to valuation, timing, diligence requirements, financing capability, transaction structure, or other terms.1
Similarly, as disclosed in STAAR's Form 8-K filing with the SEC on October 14, 2025, a representative of a privately-owned company (“Party C”) also emailed STAAR on April 7, 2025. Since the Form 8-K filing, Party C has confirmed to STAAR that “the outreach was an introductory email and was not intended as a proposal.” The email was not followe...
|
|
|
15.10.25 - 19:39
|
Broadwood Partners: All Three Leading Proxy Advisory Firms Recommend STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon (Business Wire)
|
|
|
ISS Joins Glass Lewis, Egan-Jones, and Long-Term Shareholders in Opposing Proposed Transaction
Concludes There Is No Compelling Reason for Shareholders to Support Proposed Sale of STAAR
Broadwood Cautions STAAR's Board Against Making Further Significant Decisions Without Robust Shareholder Involvement and Alignment After Mounting Opposition to the DealNEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today announced that Institutional Shareholder Services Inc. (“ISS”), a leading independent proxy advisory firm, has recommended that the shareholders of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) vote “AGAINST” the Company's proposed acquisition by Alcon Inc. (“Alcon”) (NYSE: ALC) (the “Proposed Merger”) on the GREEN Proxy Card.
ISS is the third proxy advisory firm to recommend shareholders vote “AGAINST” the Proposed Merger, joining Glass, Lewis & Co., LLC (“Glass Lewis”) and Egan-Jones Ratings Company...
|
|
|
|
|
|
|
14.10.25 - 20:30
|
Broadwood Partners Comments on STAAR Surgical′s Late and Troubling Disclosure in Deeply Flawed Sale Process to Alcon (Business Wire)
|
|
|
STAAR Belatedly Acknowledges Alternative Interest in Acquiring the Company
Reveals Entire Board Was Not Aware of Additional Interest When Recommending for Alcon Transaction
Broadwood Urges All Shareholders to Vote “AGAINST” Proposed Acquisition by AlconNEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on the recent Current Report on Form 8-K filed by STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) with the U.S. Securities and Exchange Commission (“SEC”) of a “supplement” to the Company's definitive proxy statement, filed on September 16, 2025, in connection with the proposed acquisition of STAAR by Alcon Inc. (“Alcon”) (NYSE: ALC). Broadwood, which owns 27.5% of STAAR's outstanding common stock, continues to urge its fellow shareholders to vote on its GREEN Proxy Card “AGAINST” the proposed acquisition on the terms announced August 5, 2025.
Neal C. Bradsher, Broadwood Founder and President, sa...
|
|
|
10.10.25 - 19:12
|
Broadwood Partners Issues Letter to STAAR Surgical′s Board Questioning Its Diligence in Rush to Reaffirm Support for Alcon Sale (Business Wire)
|
|
|
Raises Concerns About Whether the Board Fulfilled Its Fiduciary Duty of Care in Doubling Down on Its Commitment to Proposed Transaction
Renewed Support Comes After Stunning Revelation STAAR CEO and Chair Failed to Disclose Inbound Interest in Acquiring the Company to Rest of BoardNEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA). Broadwood, which owns 27.5% of STAAR's outstanding common shares, continues to urge its fellow shareholders to vote on its GREEN Proxy Card “AGAINST” the proposed acquisition of STAAR by Alcon Inc. (“Alcon”) (NYSE: ALC) on the terms announced August 5, 2025.
Shareholders can find additional information at www.LetSTAARShine.com.
October 10, 2025
STAAR Surgical Company
25510 Commercentre Dr.
Lake Forest, CA 92630
Dear Members of the Board:
Your carelessness continues to...
|
|
|
|
|
08.10.25 - 17:45
|
STAAR Surgical Board of Directors Reiterates Unanimous Recommendation that STAAR Stockholders Vote “FOR” the Alcon Merger Agreement on WHITE Proxy Card (Business Wire)
|
|
|
Comments on Glass Lewis ReportLAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today provided the following statement in response to a report issued by Glass, Lewis & Co., LLC (“Glass Lewis”) related to STAAR's pending merger with Alcon (SIX/NYSE: ALC):
The STAAR Board of Directors and management team strongly disagree with the recommendation issued by Glass Lewis. Alcon is paying STAAR stockholders a 59% premium to the 90-day VWAP, whereas Broadwood's proposal to vote down the merger could allow Broadwood to take control without paying any premium to other stockholders.
STAAR stockholders have a choice:
Vote For:
Vote Against:
✓ $28.00 per share all-cash offer
x $18.49 per share prior to announcement
✓ Certain and immediate cash value
x STAAR expects that its valuation would face considerable downward pressure in the event of a vo...
|
|
|
|
|
06.10.25 - 22:03
|
Yunqi Capital, One of STAAR Surgical Company′s Largest Shareholders, Reiterates Its Opposition to the Proposed Merger with Alcon (Business Wire)
|
|
|
STAAR Continues to Significantly Underestimate the Strength of the Business and Future Prospects and Misrepresent Its Performance, Competitive Position, and Market Penetration
Incentives for STAAR's CEO Are Not Aligned with Shareholders
Shareholders Should Preserve the Value of Their Investment and Vote Against the Proposed MergerHONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ:STAA), today released the following open letter reiterating its opposition to the proposed sale to Alcon Inc. (SIX/NYSE:ALC) on the terms announced on August 5, 2025.
October 7, 2025
Dear Fellow STAAR Surgical Shareholders:
After reviewing the recent public communications from STAAR, including STAAR's investor presentation issued on September 26, 2025, titled “Alcon Merger Maximizes Value for Stockholders – STAAR Surgical – Sept...
|
|
|
06.10.25 - 14:33
|
Broadwood Partners Issues Letter to STAAR Surgical′s Board Questioning Its Judgment in Proposed Sale to Alcon (Business Wire)
|
|
|
Contends There Is No Business Justification for the Board's Decision to Sell the Company for $28 Per Share Now After Rejecting $58 Per Share from Alcon Last Year
Encourages Shareholders to Vote “AGAINST” the Proposed AcquisitionNEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA). Broadwood, which owns 27.5% of STAAR's outstanding common shares, continues to urge its fellow shareholders to vote on its GREEN Proxy Card “AGAINST” the proposed acquisition of STAAR by Alcon Inc. (“Alcon”) (NYSE: ALC).
Shareholders can find additional information at www.LetSTAARShine.com.
October 6, 2025
STAAR Surgical Company
25510 Commercentre Dr.
Lake Forest, CA 92630
Dear Members of the Board:
You have decided it is time to sell STAAR for $28 per share. As you know, we strongly disagree with that decision.
On...
|
|
|
06.10.25 - 13:33
|
STAAR Surgical Addresses Broadwood Partners′ Flawed, Misleading, and Misinformed Claims (Business Wire)
|
|
|
Alcon Merger Represents 59% Premium to the 90-Day VWAP Prior to the Announcement
The STAAR Board of Directors Strongly Encourages ALL Stockholders to Vote “FOR” the Alcon Merger on the WHITE Proxy CardLAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued the following statement with respect to the flawed, misleading, and misinformed claims recently made by Broadwood Partners, L.P.:
Broadwood's recent presentation recycles flawed, misleading, and misinformed claims about the process and considerations leading up to STAAR's agreement with Alcon and the certain, compelling, premium cash value this transaction provides. Broadwood's claims have been refuted in detail in STAAR's investor materials, including in its press release “STAAR Surgical Publishes Presentation Highlighting Compelling, Certain Cash Value Offered by Alcon Merger and Meaningf...
|
|
|
06.10.25 - 13:33
|
STAAR Surgical: Independent Industry Analysts Recognize Merits of Alcon Merger, the Value It Provides, and the Downside Risks Facing STAAR on Standalone Basis (Business Wire)
|
|
|
All STAAR Stockholders Encouraged to Vote “FOR” Alcon Merger on the WHITE Proxy CardLAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today highlighted commentary from numerous independent industry analysts who recognize that STAAR's merger with Alcon (SIX/NYSE: ALC) – and the compelling, certain, premium cash value it provides – is the best path forward for STAAR stockholders.
Stephen Farrell, CEO of STAAR, said, “Prior to the Alcon transaction, the median sell-side analyst price target for STAAR was only $19.00 per share. It is clear that industry analysts recognize the downside risks facing STAAR and STAAR stockholders, and the compelling, certain, premium $28 per share cash value provided by the Alcon merger. If the Alcon merger agreement is not approved on October 23, it could be a deterrent to any future buyers and there is no guarantee that ...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
